selectION has established an efficient technology platform to develop highly selective peptide blockers for ion channels. Our most advanced drug candidate is si-544 which is a best-in-class Kv1.3 blocker for treatment of effector memory T cell (TEM) driven diseases.
The company is well positioned to expand its range of class-leading ion channel blockers by targeting additional potassium, sodium, calcium and chloride channels, which will lead to other clinical applications in pain management and oncology.
GSV is a San Diego based investment firm, that provides capital, management and advisory services to early-stage life sciences companies with disruptive technologies that have the potential to substantially improve the conditions of life.
BioM is a venture fund by the Bavarian local government that offers young biotech companies extensive customized assistance along the road towards a successful existence. As an independent financing facility, BioM manages a seed fund and invests in young biotech companies in the Munich area.
Mey Capital Matrix GmbH is a Munich-based venture capital company.
The Company received several grants from federal or regional programs including:
m4 Leading Edge Cluster